HDL and cardiovascular disease

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Atherosclerosis Research

Background:

• High-density lipoprotein (HDL) cholesterol is inversely associated with coronary heart disease (CHD) risk.
• HDL's atheroprotective properties are well-established, yet its causal role in atherosclerosis is debated.
• Skepticism regarding the HDL hypothesis stems from human genetics and clinical trial outcomes.

Purpose of the Study:

• To evaluate the current understanding of the relationship between HDL and atherosclerosis.
• To discuss the implications of recent findings and ongoing research in HDL-targeted therapies.
• To assess the potential of HDL-modulating drugs in cardiovascular disease prevention.

Main Methods:

• Review of human genetic studies.
• Analysis of clinical trial data for HDL-raising therapies.
• Examination of emerging therapeutic strategies targeting HDL function.

Main Results:

• Inconsistent results from clinical trials have cast doubt on the direct causal link between HDL and atherosclerosis.
• Despite uncertainties, novel therapeutic interventions targeting HDL are progressing through clinical development.
• Cholesteryl ester transfer protein (CETP) inhibitors are in late-stage development.

Conclusions:

• The definitive impact of HDL-targeted therapies on coronary heart disease events is yet to be determined.
• Further research is needed to elucidate the complex role of HDL in cardiovascular health.
• The development of drugs that enhance HDL function, including reverse cholesterol transport, shows promise for future cardiovascular risk management.